Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-69
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

The goal of this clinical trial is to assess whether, over an observation period of 3 years, there is a reduction in cardiovascular risk, and the extent of this reduction, in a group of adult kidney transplant patients undergoing tailored exercise combined with dietary counselling compared to a group of patients following the 'standard of care'.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinically stabilised male and female kidney transplant patients (assessment by the referring transplant centre)

Minimum age, 30 years;

Maximum age, 69 years;

Period since transplantation: from 6 months (subject to clinical stability being achieved) to 10 years;

Disqualifiers

Patients unable to follow the prescription,

Recent acute cardiovascular event (< 2 months),

Unstable angina,

Hyperkinetic/hypokinetic arrhythmias not controlled by therapy, and with signs of haemodynamic impairment,

Trial design

Design model

Parallel

Treatments tested in this trial

  • lifestyle intervention

    Behavioral

    exercise and dietary counselling

Treatment groups

275 Participants
are divided into 2 treatment groups
Group A: Group A, lifestyle interventionExperimental treatment 1 intervention
Group B: Group BNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Cardiovascular risk reduction

reduction of at least 1% in the cardiovascular risk score - Framingham score - over the observation time. This score estimates the risk of developing a cardiovascular event over a 10-year period and is calculated in relation to the outcome from the following identifiable variables in normal clinical practice: * Sex * Age * Systolic pressure value * Treatment for hypertension (yes/no) * Smoker (yes/no) * Diabetes (yes/no) * HDL value * Total cholesterol value

Time frame
From enrollment to the end of the treatment (3 years)

Secondary outcomes

1

Renal function

The trend of renal function assess by eGFR using the CKD-EPI formula

Time frame
From enrollment to the end of the treatment (3 years)
2

Gut microbiota analysis

The relative abundances of the main intestinal bacterial groups and hence the effect of physical exercise on the gut microbiota

Time frame
From enrollment to the end of the treatment (3 years)
3

Inflammatory status

The variation of the inflammatory status (by CRP analysis, IL-6, ferritin, cortisol)

Time frame
From enrollment to the end of the treatment (3 years)
4

Quality of Life (QoL)

The perception of quality of life through the SF12 questionnaire (composite items of physical and mental health)

Time frame
From enrollment to the end of the treatment (3 years)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

CNT (Centro Nazionale Trapianti)

Collaborator

Azienda Unità Sanitaria Locale della Romagna

Collaborator